Casopitant

Key facts

Active substance
Casopitant
Therapeutic area
Oncology
Decision number
P/6/2009
PIP number
Casopitant
Pharmaceutical form(s)
  • Powder for solution for infusion
  • Film-coated tablet
Condition(s) / indication(s)
Nausea and vomiting
Route(s) of administration
  • Intravenous infusion
  • Oral use
Contact for public enquiries
Glaxo Group Limited

E-mail: eu.paediatric-plans@gsk.com
Tel. +44 (0)20 8990 3650

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

Topics

How useful was this page?

Add your rating